BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines income Statement — Total revenue ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations (DB)
Latest, Q2 2026
1,705
Period ended Jun 30, 2026
Change on a year earlier
+29.6%
1,315 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
40
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up income statement — total revenue ($m)
- Cost of sales — product ($M)175 · Q2 2026
- Gross profit ($M)1,531 · Q2 2026
- Research and development expense ($M)612 · Q2 2026
- Selling, general and administrative expense ($M)593 · Q2 2026
- Total operating expenses ($M)1,206 · Q2 2026
- Income (loss) from operations ($M)325 · Q2 2026
- Income (loss) before income taxes ($M)313 · Q2 2026
- Income tax expense ($M)75.5 · Q2 2026
- Net income (loss) ($M)237 · Q2 2026
- Earnings (loss) per ordinary share — Basic ($/sh)0.16 · Q2 2026
- Earnings (loss) per ordinary share — Diluted ($/sh)0.16 · Q2 2026
- Weighted-average basic ordinary shares outstanding (M)1,451 · Q2 2026
- Weighted-average diluted ordinary shares outstanding (M)1,505 · Q2 2026
Cite this data
StockData. (2026). BeOne Medicines Income Statement — Total revenue ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/fs_income_stmt
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.